230 related articles for article (PubMed ID: 27029823)
41. Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.
Dave N; Gopalakrishnan S; Mensing S; Salem AH
Clin Transl Sci; 2019 Nov; 12(6):625-632. PubMed ID: 31268229
[TBL] [Abstract][Full Text] [Related]
42. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
43. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; Bodin F; Weidekamm E; Kutz K; van Giersbergen P
J Clin Pharmacol; 2002 Mar; 42(3):283-9. PubMed ID: 11865964
[TBL] [Abstract][Full Text] [Related]
44. Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers.
Drabant S; Nemes KB; Horváth V; Tolokán A; Grézal G; Anttila M; Gachályi B; Kanerva H; Al-Behaisi S; Horvai G; Klebovich I
Eur J Pharm Biopharm; 2004 Nov; 58(3):689-95. PubMed ID: 15451546
[TBL] [Abstract][Full Text] [Related]
45. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC
J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
[TBL] [Abstract][Full Text] [Related]
46. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies.
Preskorn S; Ereshefsky L; Chiu YY; Poola N; Loebel A
Hum Psychopharmacol; 2013 Sep; 28(5):495-505. PubMed ID: 24014143
[TBL] [Abstract][Full Text] [Related]
47. The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers.
Lim A; Wang-Smith L; Kates J; Laurent A; Kumar P; Laliberte K
J Clin Pharm Ther; 2013 Dec; 38(6):450-5. PubMed ID: 23927483
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Pithavala YK; Chen Y; Toh M; Selaru P; LaBadie RR; Garrett M; Hee B; Mount J; Ni G; Klamerus KJ; Tortorici MA
Cancer Chemother Pharmacol; 2012 Jul; 70(1):103-12. PubMed ID: 22644797
[TBL] [Abstract][Full Text] [Related]
49. Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.
Zhang M; Xu C; Ma L; Shamiyeh E; Yin J; von Moltke LL; Smith WB
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):315-21. PubMed ID: 27136912
[TBL] [Abstract][Full Text] [Related]
50. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
[TBL] [Abstract][Full Text] [Related]
51. [Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets].
Drabant S; Klebovich I; Gachályi B; Renczes G; Farsang C
Acta Pharm Hung; 1998 Sep; 68(5):294-306. PubMed ID: 9805816
[TBL] [Abstract][Full Text] [Related]
52. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
[TBL] [Abstract][Full Text] [Related]
53. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
Falcoz C; Jenkins JM; Bye C; Hardman TC; Kenney KB; Studenberg S; Fuder H; Prince WT
J Clin Pharmacol; 2002 Aug; 42(8):887-98. PubMed ID: 12162471
[TBL] [Abstract][Full Text] [Related]
55. Oral bioavailability of ospemifene improves with food intake.
Koskimies P; Katila K; Lammintausta R; Aaltonen AM; Vuorinen J; Saarni O; Scheinin M
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):787-94. PubMed ID: 24040848
[TBL] [Abstract][Full Text] [Related]
56. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
57. Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet.
Badawi M; Chen X; Marroum P; Suleiman AA; Mensing S; Koenigsdorfer A; Schiele JT; Palenski T; Samineni D; Hoffman D; Menon R; Salem AH
Clin Drug Investig; 2022 Aug; 42(8):657-668. PubMed ID: 35829925
[TBL] [Abstract][Full Text] [Related]
58. A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic.
Alaarg A; Menon R; Rizzo D; Liu Y; Bien J; Elkinton T; Grieme T; Asmus LR; Salem AH
Clin Transl Sci; 2022 Jan; 15(1):244-254. PubMed ID: 34416076
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.
Salem AH; Hu B; Freise KJ; Agarwal SK; Sidhu DS; Wong SL
Clin Drug Investig; 2017 Mar; 37(3):303-309. PubMed ID: 27910036
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
